Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
4D Pharma, based in the UK and led by Duncan Peyton (CEO) and Alex Stevenson (CSO), was founded and listed on the London Stock Exchange AIM market in January 2014.
The company is a leader in the development of live biotherapeutics in a wide range of therapeutic areas. 4D Pharma’s aim is to develop therapies using functionally active single strains of bacteria that occur naturally in the healthy human microbiome.
The current fund-raising round will enable the company to continue their existing clinical trials for the treatment of IBS, cancer and asthma.
4D is looking to achieve positive data read outs in 2020 in IBS, Cancer and Asthma.
4D Pharma was formed in February 2014, and is a leader in the area of Live Biotherapeutics (LBPs), a novel and emerging class of drugs. LBPs are defined by the FDA as biological products that contain a live organism, such as a bacterium, applicable to the prevention, treatment or cure of a disease. 4D has a proprietary platform, MicroRx®, that identifies LBPs based on function and mechanism.
Bryan, Garnier & Co acted as Joint Bookrunner and Joint Broker in the £22m follow-on fundraising. The transaction team have been working with 4D’s management since 2014. On this transaction the Bryan, Garnier & Co team worked together with management to widen the shareholder base by bringing in new investors from the US and the UK.
The funds raised will enable the company to progress its five ongoing clinical trials in the therapeutic areas of IBS, Cancer and Asthma.
This marks another landmark transaction for Bryan, Garnier & Co’s healthcare practice and follows on from our recent fund raisings for Geneuro, BionTech and Celyad.